Company broadens footprint in Singapore, New Zealand, India and Northern Asia; appoints key hires in Asia Pacific Region
SYDNEY, Aug 24 (Bernama-BUSINESS WIRE) -- CrowdStrike® Inc., the leader in cloud-delivered endpoint protection, today announced the rapid expansion of its Asia Pacific (APAC) operations on the heels of triple-digit bookings growth. The company has established offices and headcount in key markets including Singapore, New Zealand, India and Northern Asia. Increased demand within the APAC region for CrowdStrike Falcon®, the first cloud-based endpoint protection platform, continues to spike as organizations replace legacy antivirus (AV) solutions with next-generation technology. CrowdStrike Falcon is the only platform that unifies next-generation AV, endpoint detection and response (EDR), and a 24/7 threat hunting service — all delivered via a single lightweight agent. With CrowdStrike Falcon, organizations can replace their AV or augment it with a full-scale endpoint protection solution, powered by a cloud-native architecture and artificial intelligence/machine learning. While CrowdStrike opened APAC headquarters in June 2016, the organization has had customers within the region for more than four years. Since then, CrowdStrike has seen growing momentum in its business and operations, sales growth, and a rapidly expanding customer base. This May, CrowdStrike completed a $100 million Series D funding round, led by existing investor Accel along with CapitalG (formerly Google Capital), Warburg Pincus, March Capital Partners and regional investor Telstra. This round of funding will help CrowdStrike further accelerate its APAC expansion to meet the spiking demand for its Falcon platform. In tandem with expanding operations, CrowdStrike has made multiple strategic hires to continue investment in the APAC region including regional director for India and SAARC, APAC director of Channel and Alliances, and regional Sales and Marketing managers for New Zealand, Southeast Asia and Victoria, Australia. CrowdStrike’s operations in APAC now include Australia, New Zealand, Singapore, India, and parts of Northern Asia. Other regional milestones include:
Supporting Quotes: Kevin O’Sullivan, head of Security Services, Kinetic IT “Today, customers are looking to move away from point products and adopt comprehensive solutions to not only transform their legacy AV but also add capabilities to detect and respond to advanced attacks. CrowdStrike Falcon offers exactly that and enables customers to stop breaches regardless of how threats continue to evolve. CrowdStrike and Kinetic IT share a commitment to putting the customer first and delivering best-of-breed solutions to drive value and ROI and we look forward to continuing to our productive partnership.” Michael Ostrowski, regional vice president of Sales, APAC at Proficio “As a global, next-gen cybersecurity services provider, Proficio is continually focused on providing its clients with state-of-the-art monitoring, detection and response solutions like CrowdStrike’s Falcon platform. Through our valued partnership with CrowdStrike, we are able to offer our clients the most comprehensive and effective solution to stop modern-day attacks and give them a definitive advantage against the rising tide of threats that they are facing not just in the APAC region but globally as well. The CrowdStrike Falcon platform not only improves our overall visibility into our customers’ environment but also allows us to provide better actionable intelligence, recommendations and remediation.” Andrew Littleproud, vice president of APAC, CrowdStrike “The CrowdStrike Falcon platform delivers to customers maximum protection against modern-day threats, along with best-in-class performance, efficacy, and efficiency. This powerful combination has allowed us to set a new standard in endpoint security, which is driving incredible momentum in our sales across APAC. We are excited to expand our presence in APAC countries and will continue to invest within the region throughout the rest of 2017.” About CrowdStrike® CrowdStrike is the leader in cloud-delivered endpoint protection. The CrowdStrike Falcon® platform offers instant visibility and protection across the enterprise and prevents attacks on endpoints on or off the network. CrowdStrike Falcon deploys in minutes to deliver actionable intelligence and real-time protection from Day One. Falcon seamlessly unifies next-generation AV with best-in-class endpoint detection and response, backed by 24/7 managed hunting. Its cloud infrastructure and single-agent architecture take away complexity and add scalability, manageability, and speed. CrowdStrike Falcon protects customers against all cyber attack types, using sophisticated signatureless artificial intelligence/machine learning and Indicator-of-Attack (IOA) based threat prevention to stop known and unknown threats in real time. Powered by the CrowdStrike Threat Graph™, Falcon instantly correlates over 50 billion security events from across the globe to immediately prevent and detect threats. There's much more to the story of how Falcon has redefined endpoint protection but there's only one thing to remember about CrowdStrike: We stop breaches. Learn more: https://www.crowdstrike.com/ Follow us: Blog | Twitter © 2017 CrowdStrike, Inc. All rights reserved. CrowdStrike®, CrowdStrike Falcon®, CrowdStrike Threat Graph™, CrowdStrike Falcon Prevent™, Falcon Prevent™, CrowdStrike Falcon Insight™, Falcon Insight™, CrowdStrike Falcon Discover™, Falcon Discover™, CrowdStrike Falcon Intelligence™, Falcon Intelligence™, CrowdStrike Falcon DNS™, Falcon DNS™, CrowdStrike Falcon OverWatch™, and Falcon OverWatch™ are the trademarks of CrowdStrike, Inc. All other brands, products, or service names are or may be trademarks or service marks of their respective owners. Contacts CrowdStrike, Inc. Ilina Dimitrova, 202-340-0517 [email protected] Source: CrowdStrike, Inc.
0 Comments
KUALA LUMPUR, Aug 24 (Bernama) -- Green city experts from the United Nations and the Southeast Asian region will share and discuss the benefits, challenges, pragmatism and potential of building zero waste and zero plastic cities in the business field at the Green City Forum on Sept 8.
As part of the Selangor Smart City and Future Commerce Convention 2017, the forum will be held at Setia City Convention Centre, Shah Alam, featuring regional speakers from Indonesia and the Philippines together with local waste management experts and environmental entrepreneurs, to share their thoughts on how to make businesses green yet profitable. The keynote speech will be delivered by environment programme coordinator of the UN Centre for Regional Development, Choudhury Rudra Charan Mohanty to explore the pragmatism, challenges and potential of realising efficient and zero waste societies in Malaysia. Meanwhile, the fireside chat session titled 'Green Profit, Green Opportunities' will be hosted by Selangor Princess Tengku Zatashah Sultan Sharafuddin Idris Shah and chief executive officer of The Body Shop (Malaysia) Datin Mina Cheah-Foong. "This session will explore the imminent threats on economies, corporations and even cities, and how their businesses and communities are employing greener growth and sustainability, as well as resilient strategies to mitigate and minimise threats to our future," said Selangor Information Technology & E-Commerce Council (SITEC) in a statement, today. Apart from that, the forum will also feature regional panelists during the panel session titled 'Breaking Free From Plastic and Building Green Cities' such as the CEO of Greeneration Indonesia Muhammad and executive chairman of Setia Haruman Sdn Bhd Ahmad Khalif Mustapa Kamal. --BERNAMA LIER, Belgium, Aug 23 (Bernama-GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Manuport Logistics in Belgium is using the Descartes Verified Gross Mass™ (Descartes VGM™) solution to help its customers comply with the International Convention for the Safety of Life at Sea (SOLAS) regulations for container weight requirements.
“The long-standing relationship Manuport has with Descartes played an important role in our selection of the Descartes VGM solution; however, it was the rapid implementation capabilities that really differentiated Descartes,” said Luc Geerts, Strategic Accounts Manager at Manuport Logistics. “In addition, Descartes has an impressive track record in networked communication and the Descartes VGM solution uses a similar Descartes standard message format as we do for managing shipments. In the maritime industry where messaging standards are limited, Descartes greatly simplifies the process of communicating with different stakeholders in our supply chain.” mrem.bernama.com/viewsm.php?idm=29863 TOKYO, Aug 21 (Bernama) --
Genesis Healthcare Co. has announced the completion of a new share issue worth 1.4 billion yen for allotment to Rakuten Inc. Furthermore, Rakuten's Chairman and CEO will join Genesis Healthcare's Board of Directors as an External Board Director. As a result of the new stock offering, Genesis Healthcare's capital has increased to 2.1 billion yen, one of the largest paid-in-capital levels among genetic testing companies in Japan. Genesis Healthcare, founded in 2004, already manages one of the largest genetic databases in Asia and Japan, with data of approximately 520,000 individuals as of August, 2017, and plans to increase its database size to one million by 2020. While Genesis Healthcare offers various genetic testing services to the government, medical community, academia, industry and consumers, it also offers healthcare and disease prevention test kits and IT services under the consumer brand "GeneLife" in order to enrich people's lives through personalized genetic testing. Genesis Healthcare's Co-Founder and President, Dr. Iri Sato Baran, commented: "The investment by Rakuten, a Japan leader in Internet services, will allow us to increase awareness of genetic information technology through digital healthcare for the betterment of personalized health and self-medication." "Forward-thinking technologies like Genesis Healthcare's genetic health analysis and a deeper understanding of responsible self-medication are essential to finding innovative responses to increasing health costs and the rising awareness of health issues in Japan," commented the Rakuten Chairman and CEO, Hiroshi "Mickey" Mikitani. "With this investment, we would like to see Genesis Healthcare take a leading role in furthering the understanding and adoption of genetic health testing in Japan." mrem.bernama.com/viewsm.php?idm=29849 SINGAPORE, Aug 21 (Bernama-BUSINESS WIRE) -- A.M. Best has assigned a Long-Term Issuer Credit Rating (rating) of “bbb-” to CBL Corporation Limited (CCL) (New Zealand). The outlook assigned to the rating is stable.
CCL is a listed company on the Australian Securities Exchange and the New Zealand Stock Exchange. The lead insurance subsidiary within this group is CBL Insurance Limited (CBL), a non-life insurer that specializes in writing building- and construction-related credit and financial surety insurance, bonding and reinsurance. CCL’s rating reflects the use of typical notching from CBL’s current rating, which is “a-”, with a stable outlook. On a consolidated basis, CCL maintains moderate financial leverage, and A.M. Best expects CCL’s interest coverage ratios to continue to support its guideline for the assigned rating. Factors that may lead to negative rating actions for CCL include deterioration in operating performance in the subsidiary insurance operations or a decrease in CBL’s risk-adjusted capitalization to a level that would no longer support its current ratings. Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication. mrem.bernama.com/viewsm.php?idm=29845 KYOTO, Japan, Aug 22 (Bernama-BUSINESS WIRE) -- Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001):
For their second consecutive year, the Murata Cheerleaders will perform their synchronized dance at Japanese Technology Week at Tech Dome Penang this year. These innovative, world’s first cheerleading robots will be promoting latest technologies, unique Japanese innovations, and the ability of electronics to enrich human lives. In cooperation with Tech Dome Penang, Murata will organize four demonstrations on 26th and 27th, and three demonstrations on 28th of August. Join us at the Japanese Technology Weekend at Tech Dome Penang and witness the impressive capabilities of the Japanese robots! Event Overview Time Saturday, August 26, and Sunday, August 27, 2017 Demonstrations commence at: (length of the demo ~20 min) 11:00; 13:00; 15:00; 16:00 Monday, August 28, 2017 Demonstrations commence at: (length of the demo ~20 min) 11:00; 13:00; 15:00 Place Tech Dome Penang, KOMTAR Geodesic Dome, Jalan Penang, 10000 George Town, Pulau Pinang, Malaysia About Tech Dome Penang Tech Dome Penang (TDP) is a science and discovery center situated in Georgetown, Penang. It is a not-for-profit organization established to motivate and inspire young people concerning Science and Technology by allowing them to experience science in a fun way. TDP was open to the public in July 16th 2016. Apart from the 120 interactive exhibits which demonstrate scientific concepts to our visitors, TDP also runs special projects, workshops, education programs and team building activities. For more information, visit Tech Dome Penang’s website http://techdomepenang.org/ About Murata Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata's website at www.murata.com. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51671076&lang=en Contacts Media Contact Murata Manufacturing Co., Ltd. Yoshihiko TAKEDA, +81 (0)75 955 6786 Corporate Communications Office [email protected] Source: Murata Manufacturing Co., Ltd. ---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration
---Contributions of Capital, More Than 200+ Issued and Pending Patents, Pre-Clinical and Clinical Assets and Commercial Products Obtained from Companies Including Celgene Corporation, Sorrento Therapeutics (Nasdaq: SRNE), United Therapeutics (Nasdaq: UTHR), and Human Longevity, Inc. WARREN, N.J., Aug 22 (Bernama-BUSINESS WIRE) -- Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:
“Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs,” said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. “With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases.” Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc. The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta – an ethical and renewable source of usable biomaterials. Celularity’s development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors. Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, “The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases." Dr. von Eschenbach added "Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world's unmet medical needs." *Interfyl is a registered trademark of Alliqua BioMedical, Inc. Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, “We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularity’s technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.” About Celularity, Inc. Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visit www.celularity.com. Follow Celularity on Social Media: @Celularity. About United Therapeutics United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. About Sorrento Therapeutics Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visit http://sorrentotherapeutics.com About Human Longevity, Inc. Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com Contacts Media: For Celularity Olivia Goodman, 212-715-1597 [email protected] or Sorrento Therapeutics, Inc. Alexis Nahama, DVM, 858-203-4120 [email protected] Source: Celularity, Inc. Instructed by Artist Hiroki Maeno for Overseas Guests
TOKYO, Aug 17 (Bernama-BUSINESS WIRE) -- Keio Plaza Hotel Tokyo, one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, starts special 45 minute classes to teach overseas guests about “Ikebana” flower arrangement which will be held on every other Thursday beginning from August in a private room for JPY3,000 per participant. Instruction and commentary will be provided by the renowned flower arrangement artist Hiroki Maeno. Flower arrangement artist Hiroki Maeno has created special and unique flower arrangements for display in the main lobby of our hotel with each change of the seasons, four times a year. His newest flower arrangement will be 2.7 meters wide by 5 meters tall and made from bamboo, greeneries and white enkianthus, which are symbolic of cool in Japan, to provide aesthetic relief from the summer heat. This arrangement will be displayed from August 4 to 18, 2017 for all hotel guests to enjoy. The Keio Plaza Hotel has offered “Ikebana” flower arrangement workshops to guests staying at our hotel on an ad hoc basis until now, but in response to strong demand we will now begin offering these workshops on a regular basis and to a wider audience that includes visitors not staying at our Hotel. mrem.bernama.com/viewsm.php?idm=29825 Enabled by the Ascom Myco smart device, the new Koutio Médipôle is realizing improved care delivery through seamless information flow from the point of care to anywhere.
BAAR, Switzerland, Aug 16 (Bernama-GLOBE NEWSWIRE) -- The new Koutio Médipôle hospital in the New Caledonian capital Nouméa, located in the southwest Pacific Ocean, has optimized patient care communications and responsiveness for the new 645-bed facility by deploying Ascom Myco Wi-Fi devices to support clinician teams and Ascom Myco Wi-Fi/GSM handsets, used across paramedic teams. The Ascom solution is seamlessly aligned with clinical workflow and applications (nurse call, pneumatic conveyors, patient transport, etc.). The hospital also utilizes a Mercury server and software solution that automatically forwards all alerts related to emergency tasks, nurse call and patient transportation location independently to the correct staff in charge via Ascom Myco smartphones and text messages. These integrated installations strengthen the Information and Communication Technology (ICT) infrastructure of the facility and increase care efficiency by displaying patient transport information made accessible and visible on the Ascom Myco handset. This improves transport efficiency by avoiding common errors and contributes to better patient care and safety. Frédéric Dosch, Deputy Director in charge of information and biomedical systems emphasizes: “Our information system combines different best of breed applications and is now enhanced with top-notch mobility features.” The Nouméa Hospital thrives to ensure premium performances for data and communication management. The Ascom Myco and the Mercury server are solid foundations clinicians can build on. Dosch explains: “In the near future, we plan to enable two new features for our transporters: geolocation and patient identity verification barcode scanning with Myco. These will boost our efficiency and ensure that a transport request is delivered to a transporter in close proximity to the patient.” mrem.bernama.com/viewsm.php?idm=29821 |
Archives
April 2023
Categories |